A drug on the market?

被引：11

作者：

Gale, EAM ^{[1
]}

Clark, A

机构：

[1] Univ Bristol, Southmead Hosp, Div Med, Bristol BS10 5NB, Avon, England

[2] Radcliffe Infirm, Diabet Res Labs, Oxford OX2 6HE, England

来源：

LANCET | 2000年 / 355卷 / 9197期

关键词：

D O I：

10.1016/S0140-6736(99)07304-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：61 / 63

页数：3

共 27 条

[1] METABOLISM - AMYLIN AND DIABETES
AMIEL, S
[J]. LANCET, 1993, 341 (8855) : 1249 - 1250
[2] BIOPHARMACEUTICALS AND CONVENTIONAL DRUGS - CLINICAL SUCCESS RATES
BIENZTADMOR, B
DICERBO, PA
TADMOR, G
LASAGNA, L
[J]. BIO-TECHNOLOGY, 1992, 10 (05): : 521 - 525
[3] FAILURE TO ESTABLISH ISLET AMYLOID POLYPEPTIDE (AMYLIN) AS A CIRCULATING BETA-CELL INHIBITING HORMONE IN MAN
BRETHERTONWATT, D
GILBEY, SG
GHATEI, MA
BEACHAM, J
BLOOM, SR
[J]. DIABETOLOGIA, 1990, 33 (02) : 115 - 117
[4] CLARK A, 1987, LANCET, V2, P231
[5] ISLET AMYLOID - AN ENIGMA OF TYPE-2 DIABETES
CLARK, A
[J]. DIABETES-METABOLISM REVIEWS, 1992, 8 (02): : 117 - 132
[6] AMYLIN COMPARED WITH CALCITONIN-GENE-RELATED PEPTIDE - STRUCTURE, BIOLOGY, AND RELEVANCE TO METABOLIC DISEASE
COOPER, GJS
[J]. ENDOCRINE REVIEWS, 1994, 15 (02) : 163 - 201
[7] PURIFICATION AND CHARACTERIZATION OF A PEPTIDE FROM AMYLOID-RICH PANCREASES OF TYPE-2 DIABETIC-PATIENTS
COOPER, GJS
WILLIS, AC
CLARK, A
TURNER, RC
SIM, RB
REID, KBM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (23) : 8628 - 8632
[8] DIABETES-MELLITUS IN MACACA-MULATTA MONKEYS IS CHARACTERIZED BY ISLET AMYLOIDOSIS AND REDUCTION IN BETA-CELL POPULATION
DEKONING, EJP
BODKIN, NL
HANSEN, BC
CLARK, A
[J]. DIABETOLOGIA, 1993, 36 (05) : 378 - 384
[9] Too soon to market
Dent, THS
Hawke, S
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7118): : 1248 - 1249
[10] NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1992
DIMASI, JA
SEIBRING, MA
LASAGNA, L
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (06) : 609 - 622

← 1 2 3 →